MLR review automation, explained.

What MLR review means: three signatures between a drug company's draft and a doctor's desk

One colitis detail aid, from the brand team's brief to FDA's inbox

1. Brief and draftThe brand team asks the agency for a tablet presentation on Veltrimab's one-year results. The agency writes it and attaches references.
2. Piece submittedMonday, October 5, 2026: version 2 enters review with 14 claims, three references and a due date.
3. Each claim checked at its pageMedical, legal and regulatory reviewers compare the piece with its sources, comment and request changes. "2 out of 3" is caught here.
4. Committee and signaturesHard calls go to the Thursday meeting. Three people sign the final version.
5. First use and Form FDA 2253Representatives start showing it on October 12. That day, the company files it with FDA.

Step 3 is what this guide is about. The medicine, people and figures in this example are fictional.

No US rule we read requires an MLR committee, and three more things that surprise newcomers

Detail aid, annotated reference, label and Form FDA 2253: the words you will meet here

Fourteen terms are defined in the one-page summary.

Medical, legal, regulatory: what each MLR reviewer answers for on a promotional piece

In shortThe three reviewers read the same pages for different failures, and the overlaps are where comments collide. A short written split of who owns which question is often the cheapest improvement a team can make. Everyone else in the room, from the coordinator to the proofreader, exists to keep those three reading the right version.

A best-practice article from DIA, an association for life sciences professionals, describes the seats plainly. The medical reviewer evaluates "scientific/medical validity and consistency with the FDA-approved labeling". Legal advises on legal risk, including fraud and abuse rules. Regulatory checks the piece against FDA's promotion rules and represents the company to the Office of Prescription Drug Promotion (OPDP), the FDA office that polices drug promotion. A meeting administrator runs the agenda, and a proofreader confirms each requested change was made.17

Companies arrange the seats differently. A small biotech may have one regulatory person reading everything, and a large one may split medical review by brand.

Which promotional pieces go through MLR review

FDA's rule sweeps widely. Brochures, booklets, mailing pieces, detailing pieces, calendars, price lists, sound recordings, film and similar matter issued by a company count as labeling when they describe a medicine; journal ads, magazine ads and broadcasts count as advertising.1 Companies usually add anything that might be read as promotion: speaker decks, rep briefing material, web pages, social posts, email, patient support material, payer slides. FDA's recent letters have reached an Instagram post, a video meeting background, an exhibit panel and a podcast.7,18,19

What the law fixes and what your company invents: promotional review rules as of November 2026

In shortIn the US, the law sets the standard for what a piece says and a filing at first use. Everything about who reviews, in what order and how fast is company practice. The UK and EU are more specific about people: their industry codes name the doctor or pharmacist who approves. Enforcement, quiet for years, rose sharply in September 2025.

The UK and EU name the person who approves a piece; the US does not

In the UK, the ABPI Code of Practice, the drug industry's own code, says promotional material "must not be issued unless its final form, to which no subsequent amendments will be made, has been certified" by one person, a UK-registered doctor or pharmacist (a UK-registered dentist for a dental-only product), who "must not be the person responsible for developing or drawing up the material".30

That signatory states that, in their belief, the piece follows the rules, is not inconsistent with the marketing authorization (the medicine's license to be sold), and is "a fair and truthful presentation of the facts". Material still in use is recertified at least every two years.30

The UK's medicines regulator, the MHRA, notes that signatories are a code requirement and "not a legal requirement", and asks companies to tell it who they are.31 That duty sits with the company's own person.

EFPIA, the European industry association, requires a scientific service with "a medical doctor or, where appropriate, a pharmacist" responsible for approving promotional material before release.32 National codes then add their own detail. The UK's complaint system is visible too: its code authority logged 262 complaints in 2025 and 161 rulings, and in 58% of cases received in 2024 at least one breach was found.34

Canada's Pharmaceutical Advertising Advisory Board offers preclearance "recognized by Health Canada for advertising directed to healthcare professionals".33 Whether those rules change the calendar is unproven. One vendor's country figures run 15.4 days in Germany and 27.2 in France under a 2023 heading, two countries under the same EFPIA Code, against 29.9 in the US for 2021, and the vendor gives no cause. Section 10 has the limits of these numbers.35,36

The MLR review package: the piece, annotated references, data on file, label versions and house rules

In shortA reviewer works from a stack of documents, and the check is only as good as the stack. The usual weak spots are the reference pointing at the wrong page, the data on file nobody else can open, and an old label version sitting beside the new one. For the fictional detail aid, 14 claims lean on six different documents.

Value, population, endpoint, timepoint: how an MLR reviewer tests one claim against its cited page

In shortFour questions catch most evidence problems: is the number the same, are the patients the same, was this the measure the study was built to test, and is it the same point in time? Worked on the fictional claim, "2 out of 3" passes the first and last and fails the two that matter. Even the approved replacement deserves a second look, because a maintenance study enrolls only those who already responded.

The arithmetic behind "2 out of 3" and "55% vs 30%"

Start with the subgroup. 67% of 141 is about 94 patients. They had responded to the induction treatment and were already in remission at week 12, and they were followed to week 52. No comparison with placebo is attached to the figure, and the authors call it descriptive. A doctor reading "2 out of 3 patients stay in remission" pictures something else: two in three of the people she might prescribe for.

The study's own test is the one the label reports. Patients who responded at week 12 were randomized again, assigned by chance to the medicine or to placebo (a dummy treatment), and at week 52, 55% and 30% were in remission. That is a 25-point difference, the number a reviewer can defend.

Why even "55% vs 30%" needs its footnote, and may need more than one

Take the replacement wording one step further. In the fictional induction study 58% of patients responded by week 12. If every responder went on to maintenance and 55% of them were in remission a year in, then of 100 patients starting the medicine, about 32 would reach that point. That is our arithmetic on fictional figures, and it counts only the responders.

FDA has made the same point in a real letter. In September 2025, FDA wrote about a TV ad for a skin medicine that promised lasting clear skin. FDA's letter gives the week 48 figures, then adds that "the maintenance period data represents a subset of IGA responders at Week 48 out of the IGA responder subset from Week 16", and that such data "does not support broad efficacy claims".37 (IGA is a doctor's score of how clear the skin is.)

The same reasoning applies to any maintenance result. A footnote explaining the population may satisfy a house rule. Whether it fixes the headline's overall impression is a medical and regulatory judgment, and FDA's rule says a true statement elsewhere does not cure a misleading one.1

What an exploratory endpoint is, and what 20 chances of a lucky result look like

A study names its main measure in advance, then often tests a planned list of others in a fixed order, so that its overall false-alarm rate stays at the promised 5%. Anything else is exploratory: useful for ideas and weak as proof. ICH's statistics guideline says multiplicity (many tests, more chances of a fluke) may call for an adjustment to the error rate.38

The arithmetic shows why. If each test has a 5% chance of a false alarm, then across 20 independent tests the chance of at least one is 1 − 0.95²⁰, about 64%.

So the fictional piece's "relief from rectal bleeding as early as week 2" (22% vs 14%, nominal p=0.03, a significance figure with no adjustment for the many tests, on a page headed "Exploratory endpoints") looks persuasive and proves little. FDA used nearly these words about an early-onset claim in a TV ad for another medicine: "Claims that draw conclusions from exploratory endpoints are misleading."39

FDA's consistent-with-labeling guidance leaves some room for data outside the label when it is "scientifically appropriate and statistically sound", so a flat ban on exploratory data is a company's house rule, a defensible and stricter one.9

We read FDA's 87 untitled letters: on professional pieces, over half attack the evidence itself

In shortFDA's letters jumped from 5 in 2024 to 63 in 2025, with 24 more in 2026 through September. TV ads dominate the count, and their problems are mostly about presentation. Pieces aimed at doctors are different: by our count, 12 of 21 letters on them object to the kind of study or analysis behind a claim, which is exactly what a page-level medical check should catch.

Other counts differ for honest reasons. King & Spalding, a law firm, counts 74 letters to drug and biologic makers in 2025, 64 untitled and 10 warning, because it adds warning letters and, it appears from a report by the law firm Covington, a letter from CBER, FDA's biologics center, that is not on OPDP's page.40,41

FDA said on September 9, 2025 that it was sending "thousands of letters" to companies and about 100 cease-and-desist letters, following a presidential memorandum, and that it was already using "AI and other tech-enabled tools to proactively surveil and review drug ads".23,42 The other guides in this series read these letters for claims wording and TV risk passages. This reading asks a different question: what kind of piece drew the letter, and did FDA challenge the evidence underneath?

Then we checked each letter for an objection to the analysis itself. Three shapes recur. A letter can fall in more than one, and we count 21 letters with at least one. A letter counts only where FDA itself makes the objection.

Real letters are quoted from FDA's own copies and only for what they say. A letter is FDA's view of a piece, and the products are named only in the source list. Letters are read from FDA's copies as posted. None of them is connected to this guide's fictional example.

Risk tiers in promotional review: when one reviewer is enough and when a piece needs the full committee

In shortReading every piece the same way spends the same hours on a resized banner and a launch TV spot. Many teams sort pieces into tiers: a fast lane, a standard lane and a full committee. FDA sets no tiers and no public study ranks them, so each tier is a judgment your company writes down, and defends.

Routing asks two questions of a piece: how much new judgment does it need, and how much harm follows if it is wrong? A banner reusing approved wording, on a brand with a stable label, carries little of either. A first TV spot for a launch carries both. Teams often set rules such as "broadcast always goes to committee" and "a new claim can never be fast-tracked".

No regulation requires any of this, and DIA's best-practice article does not cover tiers at all.17 Veeva's paper promotes "tier-based reviews", with business rules moving much of the content through streamlined lanes; that is a vendor's recommendation.47

What a weekly committee adds to the calendar, before anyone reads a word

A piece that is ready on a random day waits, on average, half the gap until the next meeting. With a weekly committee that is 3.5 days; with a meeting every two weeks, 7. If a piece misses a cut-off, add a full cycle.

That arithmetic is why many teams keep meetings for live disagreements and let reviewers read and comment in parallel between them. The DIA article describes a standing committee, and vendors report the time in review as a whole. We found no published split between waiting and reading.17

Why pieces go through more than one MLR round, and why legal approves fewest on the first pass

In shortVendors report about 1.3 to 1.5 review rounds a piece, and legal reviewers approve the fewest on the first circulation. A low rejection rate per piece still means most campaigns hit a rework, because any one of several assets can send the campaign back. No independent study has broken comments down by cause, so count your own.

The figures do not say why legal comes last. One reasonable reading is that legal reviews comparisons and wording that have no page to settle them, while a medical question often ends once the page is open. Treat that as a question to put to your own comments.

The campaign arithmetic that turns 74% first-time approval into 95% rework

Veeva's 2021 benchmark, its latest in that form we could read, says 74% of digital content is approved in the first cycle. Klick, an agency, points out that the chance of at least one asset in a ten-asset campaign needing rework is then 1 − 0.74¹⁰, about 95%, if outcomes are independent. Klick reports about 72% for a 12% rejection rate, its own figure from more than 40,000 reviews, and it sells a tool in this field.48,3

Five habits that create rounds nobody planned for

Form FDA 2253 at first use: what MLR review hands to the agency, and when

In shortWhen a piece first goes out, the company files a copy with FDA on Form FDA 2253 along with the current label. The filing is a duty, and it starts no review and brings no approval. OPDP receives over 70,000 submissions a year and comments only on request, on a 45-day goal for launch materials that it sometimes misses.

The rule's words are short: submit "at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement", with "a completed transmittal Form FDA-2253" and "a copy of the product's current professional labeling".5 For biologics, 21 CFR 601.12(f)(4) points to the same rule.12 Filing is tied to an event, so a piece signed in June and first used in October is filed in October, and someone has to watch for that date.

FDA's guidance says firms are "encouraged, but not required" to send annotated versions with ordinary 2253 submissions.15 Annotation matters more to the company than to FDA: it is the record of what supported each claim on the day it was signed.

How long MLR review takes: 14.8, 21, 24 or 29.9 days, depending on who measures and how

In shortEvery published MLR benchmark comes from a company selling something, and they measure different things. They suggest two to four weeks, with the US at the slow end. None of the reports states whether its days are business or calendar days, and we found no public figure for reviewer hours or cost per piece. Your own number is the only one you can act on.

Two details keep these numbers honest. Vodori's 14.8 days is the whole job, up from 13.8 in 2024, and its review stage is 7.6 days, up from 6.6.2 Veeva's 2021 report splits its 21 days into 6 before review and 15 in it.3

Veeva's 2025 paper adds that pre-review work ranges "from five to 150 days for each asset".47 The biggest delay may not sit in the review at all. The same paper says field teams "rarely or never use 77% of approved content".47 On day type, Veeva's product help says its Days to Approval field includes weekend days, which points to calendar days for that vendor; its reports do not say.53

Reviewer hours and cost per piece: numbers nobody publishes, and how to get your own

Reviewer hours per piece, cost per piece, errors per piece, how many comments are avoidable: we found no public figure for any of these.

EY says MLR review costs the pharma and medtech industries "tens of millions of dollars per year", with no method.4 Veeva's paper puts the industry's content spending at about $30 billion a year, and a 2019 JAMA paper put US medical marketing at $29.9 billion in 2016.47,54 Those figures show scale and say nothing about review. A two-week study of your own logged pieces will tell you more than any of them. Section 18 shows how.

Seven ways a claim gets past promotional review, and what happens when one reaches FDA

In shortThe errors that get through are often right numbers about the wrong patients, old safety text, a footnote that points nowhere, a comparison broader than its data, or risk set in small gray type. The consequences run from one public letter and a list of every similar piece to, in the worst past cases, billion-dollar settlements over wider conduct.

The little independent evidence on how often claims fail their references

Independent measurement is thin and old, and it looks at published journal ads. One often-cited study examined ads for blood pressure and cholesterol drugs in six Spanish medical journals from 1997, and in 45 of 102 retrievable claims (44.1%) "the promotional statement was not supported by the reference", most often because the slogan recommended the drug for patients other than those studied.16

A 2009 systematic review of 24 studies across 26 countries found less than 67% of claims rested on a systematic review, a meta-analysis or a randomized trial.55 Neither speaks directly to a modern company's reviewed pieces, and we found no current study that does.

What follows a letter: 15 working days, a list, and sometimes a corrective plan

An untitled letter names the piece and quotes it. FDA asks for immediate action and a response within 15 working days, listing similar communications.7 A warning letter adds a warning of legal action, "including, without limitation, seizure and injunction", and may ask for a corrective plan.19 Letters are public, and FDA posts them under the company's and product's name.

The larger cases reach far beyond one piece: DOJ lists off-label settlements of $2.3 billion (Pfizer, 2009) and $1.5 billion (Abbott, 2012), each covering wider conduct than one piece.56 A 2019 JAMA paper counted 103 settlements worth over $11 billion for off-label or deceptive marketing since 1997.54 The patient harm is harder to count. A doctor who believes a medicine helps two in three, or carries little risk, makes a worse decision with that patient, and no published figure measures it.

AI in MLR review: what software can compare, what reviewers keep, and what regulators have said

In shortSoftware is well suited to comparison: finding a page, reading a number, matching safety text word for word. Judgment stays with people: whether a piece leaves a fair impression, and whether a claim should be made at all. No regulator has written rules for AI in promotional review. Published work warns that AI citations often fail, and our PubMed and web searches found no peer-reviewed test on promotional claims.

A useful test sorts the checks. If a person could verify the answer in seconds by looking at a page, software can do the first pass and show the page. If the answer depends on how a reader will take a sentence, or on how much risk a company will accept, a person decides.

What the published evidence warns about AI and citations

The study closest to this work tested seven large language models, the kind of AI behind chatbots, and checked whether their cited sources backed what they said.57

That is about models answering freely, and a checker that opens a known page and quotes a passage is a narrower task. We searched PubMed and the web for a peer-reviewed test on promotional claim checking and found none as of November 3, 2026, which is no proof that none exists. So ask for measurements on your own pieces, including planted errors, and read vendor benchmarks as a vendor's.

EY's "at least 54% of errors" and "51% of reviewer time" come with no method on the page.4 Klick reports a 16-day shorter cycle at one unnamed client.48 Veeva's "up to 75%" appears as Veeva's estimate.47

A typical promotional review today: agency, coordinator, three reviewers, a Thursday meeting

In shortA piece passes through an agency, a brand coordinator, three reviewers and often a committee. In our planning estimate, most hours go to opening references and working through comments, and much of the calendar goes to waiting between people. Teams run the work in house with an agency's help, buy content approval software, or outsource parts of it, and the split of hours below is for you to replace.

Agency lead to committee chair: who touches an MLR submission

Where a piece's hours go when references are opened by hand

In-house reviewers, content approval software, or an outside reviewer: three ways teams run MLR

Detail aid P-2417: 14 claims pinned, four red, three signatures and a Form 2253 package

In shortThis is the example from the top of the page, inside the product. Six agents (pieces of AI software, each with one job) find every claim in the piece, open each cited source at its page, and mark each claim green, amber or red on the piece itself. Dr. Maya Chen, Omar Haddad and Lena Ortiz decide every finding and sign. Only then is the filing package built.

1

Thursday's work is in one queue, each piece with its lane and what is open

Dr. Chen starts with the review queue. P-2417, "Remission at 12 weeks and at 1 year", is in reviewer check on the full-committee lane, due October 8, with 4 red and 6 amber findings. Two new pieces wait above it: a Talvoren email from Priya Ranvelle at the agency, Wrenfield Health, and a Veltrimab rep-triggered email.

2

The piece itself is the workspace, with every claim numbered on the page

She opens P-2417. The four tablet pages fill the left of the screen, with 14 claims underlined and pinned: 4 not supported, 6 to fix, 4 supported. Clicking a pin opens its evidence on the right. Pin 6, the large line on page 2, is open first.

3

"Re-check every claim" shows the page check running, pin by pin

Pressing the button replays the agents in view. The extractor drops 14 gray pins, and each one takes its color as the reference verifier opens its page. Here 4 of 14 are done: page 7's week-2 relief rests on an exploratory endpoint, page 6 says the same as the piece, and one anchor pointed at page 5 when the result is on page 6.

4

Page 9 shows why "2 out of 3" turned red

The panel quotes the piece, then opens VLT-302 at page 9 with the passage marked. A short table sets the piece against the source. Value and timepoint match. Population and analysis do not: the 67% comes from the 141 patients already in remission at week 12, a descriptive subgroup. The panel adds that the label and the primary analysis report 55% vs 30% at week 52 in week-12 responders.

5

"Use approved claim" puts CL-036 in, with its footnote

She accepts the suggestion. Approved claim CL-036 replaces the line: "At week 52, 55% of patients were in clinical remission vs 30% with placebo†", and the footnote names the population, patients with a clinical response at week 12 who were re-randomized. Pin 6 turns green and reads "Fixed". She can undo it, send it to the agency instead, or dismiss it with a reason.

Green here means the wording matches an approved claim and its page. Part A shows why a reviewer may still ask whether a footnote is enough. In the sample's own numbers, about 32 of 100 patients starting the medicine get to that result.

6

With every finding decided, the medical signature records what it means

Dr. Chen applies the remaining suggestions she has read. Anything she unticks stays open. All 10 findings are now decided, every pin is green, and the piece is at version 3. The signature screen shows the count (10 accepted, 0 with agency, 0 dismissed, 0 open), the meaning of the signature, and asks for her password before it is written.

7

Regulatory and legal sign, and only then does the package build

Omar Haddad signs the regulatory review with label revision 09/2026 confirmed, and Lena Ortiz signs for legal, both on October 7. The packager then builds the Form FDA 2253 package: form fields, the final piece clean and annotated, the current Prescribing Information and the annotated references. P-2417 no longer needs Thursday's meeting.

8

The filing preview shows first use on October 12, and a person files

The preview lays out the transmittal details: applicant, application, material type and ID, first-use date of October 12, 2026, labeling enclosed, signatures and enclosures. Filing stays a person's act. Omar schedules it for the day representatives start using the piece, which is when the rule says it is due.5

From "similar to placebo" to a misplaced anchor: what each reviewer decides on the same detail aid

In shortThe other findings on P-2417 show the range of a review. Three more red pins need medical or regulatory judgment. Amber pins are mostly wording, anchors and required links. Each one names its page, its label section or its house rule, and each goes to the reviewer who owns that kind of question.

1

Pin 4: week-2 relief rests on an exploratory endpoint

"Relief from rectal bleeding as early as week 2" opens VLT-301 at page 7. The passage reads 22% vs 14%, nominal p=0.03, "exploratory and not controlled for multiplicity", and the authors say no conclusion on early onset should be drawn. The label describes no timepoint before week 12. The closest approved claim is CL-031: clinical response at week 12, 58% vs 33%.

2

Pin 10: "similar to placebo" against the label's own numbers

"Well tolerated, with a safety profile similar to placebo" opens the current label at page 5. Serious infections occurred in 2.1% vs 1.4%, and the new section 5.3 adds an injection-site warning. The regulatory reviewer gets a rewrite taken from the label wording.

3

Pin 11: the data on file behind "#1"

"The #1 prescribed biologic for new UC patients" opens data on file DOF-VLT-0412. It covers gastroenterology office prescribers only, new-to-brand prescriptions among advanced therapies, June to August 2026: 24.6% against 22.1%. Population, comparator and period do not match. The suggested wording qualifies it, and Lena Ortiz decides: she may also decide the line should not run at all.

4

Pin 13: safety text from the superseded label

The Important Safety Information block, the risk summary a piece carries, matches the March 2025 label word for word. The current label, revision 09/2026, added Warning 5.3 Injection-site reactions on September 18, 2026. The fix swaps in the standard safety text module for the new revision, approved by Omar Haddad on September 22.

5

Pin 9: "once-monthly" where the label says every 4 weeks

A small wording fix with a real point behind it: thirteen doses a year are not twelve. The brand guide and label section 2.2 both say every 4 weeks. The suggestion is one click, and the panel still shows its page.

6

Pin 2: right number, wrong page

"Clinical remission at week 12: 31% vs 12%" matches the publication and label section 14.1. The annotation linked page 5, and the agent moved it to Table 2 on page 6. No text changes. A wrong anchor still matters: it is the most common finding in the sample's dashboard, and it wastes the next reviewer's time.

7

Fair balance as a reading for the reviewer, 41 against a team threshold of 70

On the marked version, risk carries 14% of the words, in 8 point against a 22-point benefit headline, at 45% contrast, on the last page after the references, with no direction to the full Prescribing Information. The screen calls this evidence and leaves the verdict with a reviewer. FDA's rule asks for comparable prominence and readability and names no point size, so the threshold is this team's setting.1

8

Dismissing a finding takes a reason, and the reason goes on the record

A reviewer can disagree. Lena could dismiss the "#1" finding if another reference supports the claim. The reason is required, and it stays with the piece, so a later reader can see who overruled what and why.

9

All 14 claims and all 10 findings, for whoever prefers a list

The same evidence can be read as a table of every claim, with where it was checked and its verdict, or as findings sorted by severity and by who owns them. The steps run across the top with a Re-run link.

10

Same check on a TV script, by the second

Pieces come in other shapes. P-2421 is a 60-second TV script, with pins on the audio and video columns. Its benefit lines run at 2.6 words a second and its major statement at 3.9, and fast cuts sit under the risk audio.

FDA's rule asks that spoken risk be at least as understandable as the rest.21 By our count, no FDA letter of 2025 or 2026 raises voice pace specifically, though many raise distracting visuals.7 Pace is a useful measure for a person to weigh, and FDA has drawn no line on it.

Routing lanes, Thursday's agenda and the label watch: what an MLR operations lead runs

In shortDana Okafor, the operations lead, sets who reads what once, then sees where each piece landed. Thursday's agenda holds open judgment calls only. A label change sets off a re-check of live pieces. The dashboard shows how long approval takes, and its sample readings are design targets until a customer measures its own.

1

Ten pieces in three lanes, each with a reason

The router scores each piece and places it: fast track, one reviewer and two days; standard, three reviewers and five days; full committee, the Thursday meeting. The rules are Dana's. A person can always move a piece up.

2

The agenda carries open questions, beside a watch on the label

Thursday, October 8, 10:00 am: four pieces and their open items. Beside the agenda, the label watch reports that Veltrimab's revision 09/2026 added Warning 5.3 and retired claim CL-019, and that 7 approved, live pieces carry the old safety information.

3

One click re-reads seven live pieces against the new label

The result: five revisions to swap the safety information, and two withdrawals, one that also says "similar to placebo" and one using the retired claim. A person confirms each. The label change guide takes this step much further.

4

Claims with their pages, and label versions kept side by side

The claims library holds approved wording, its reference page, its label section, its status and how many pieces use it. Retired claim CL-019 is still listed in 7 pieces, which is the point of keeping it. References are indexed by page, and the two label versions sit together with what changed.

5

The dashboard's sample: 13.5 days, 58% in one round, routing 41, 43, 16

Median submission to approval, approved in one round, findings reviewers kept, and where pieces went. These are the sample company's readings and the solution's design targets: 13.5 days against a 29-day baseline, and 58% approved in one round. Your numbers come from your own baseline and your own run.

6

Wrong anchors top the sample's findings, ahead of unsupported claims

Of 210 findings in the last 30 days of sample data, 46 are wrong reference anchors, 38 claims not supported on the cited page and 27 outdated safety text. Dana can see where they come from by brand, and which pieces have waited longest.

7

Thresholds, signers and checks are the team's own settings

Fast track below score 30, full committee from score 60, broadcast and first pieces of a launch always to committee, fair balance line at 70, and who signs for each brand. Each check can be turned on or off, a rule can be added in a sentence, and every change is versioned and on the audit trail.

Six agents check and package; medical, regulatory and legal reviewers decide and sign

In shortEach agent has one job and a written limit. None approves a piece, signs for a person or files with FDA. On fast track one person signs; on standard and committee, three. The whole record, people and agents together, supports your compliance work, and the controls are yours to validate.

From the claim extractor to the 2253 packager: each agent's job and its limit

Dr. Chen, Omar Haddad, Lena Ortiz and Dana Okafor: the people in P-2417's record

Signers are a setting, so a UK or EU procedure can name its own people. In the UK, the signatory who certifies a piece stays your own registered doctor or pharmacist.30

Detail aids, labels and references in; pins, an agenda and a Form 2253 package out

Content approval, reference and label systems around the claim check

What another MLR round costs you: reviewer hours, missed committee slots and field dates

In shortNobody publishes a cost per piece. Published figures frame the size of the problem: a two-to-four-week trip, about one piece in four going round again, and FDA reading more closely than it has in years. The number that decides your case is your own, and you can have a first version within a week.

Six costs of a hand-checked MLR review, and how to find each number in a week

A line quoted in public, a 15-working-day scramble: MLR costs no calculator can price

What a page-level claim check returns in reviewer hours, avoided rounds and days to the field

In shortThree levers pay for the check: hours released from opening references, rounds avoided by catching problems early, and days given back to a brand. Hours count only if you decide what they are for. Below a certain volume, a well-kept library and clearer house rules will return more than any software.

Reference hours, fewer rounds and committee time: where MLR automation earns its keep

Work out your MLR return from pieces a year, hours and your return rate

A team reviewing 60 pieces a year on one brand may gain more from a current claims library, one written house rule list and a parallel comment habit than from new software. Volume, agencies and the number of label changes are what change the answer.

How ready your MLR process is: lanes, references, label versions, signers and baselines

In shortPick the answer closest to your team today. Eight questions score 0 to 2, and the last is for reflection. The meter adds up as you go, and each question says why it matters and what a strong answer sounds like.

A low MLR score means fixing lanes and references before buying anything

What to ask an MLR review software vendor about pages, subgroups, labels and signatures

In shortAsk each vendor the same questions, us included. The answers show whether a tool checks the content of a cited page or only confirms that a reference is attached, whether reviewers can see why, and how it behaves when it is wrong.

Testing MLR automation on 40 past pieces with planted errors, then a parallel run

In shortStart with pieces you have already reviewed, so nothing is at risk and the right answers are known. Plant errors of the kinds that matter, score catches and false alarms, then run alongside your live process on one brand. Decide on four numbers set in advance.

1. Weeks 1 to 3: baselineTime ten pieces and code the comments on 50. Set your four decision numbers.
2. Weeks 2 to 5: test setPick 40 past pieces across channels, and plant 40 errors: subgroups, old safety text, wrong anchors, widened comparisons.
3. Weeks 4 to 6: blind runThe tool checks the test set. A reviewer who did not plant the errors scores it.
4. Weeks 6 to 12: parallel runLive pieces on one brand, both ways. Your reviewers still sign under your procedure.
5. Weeks 12 to 14: decideScore, read every miss, and decide.

Scoring the pilot: catch rate, false alarms, reviewer hours and first-pass rate

MLR review questions answered: process, committee, Form 2253, timing and AI

In shortThe questions reviewers, agencies and buyers search for, each answered on its own.